The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | A deeper look at the genomics of multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the need to better understand the genomics of multiple myeloma, and the benefit of observing disease progression from early stage monoclonal gammopathy of undetermined significance (MGUS) to symptomatic multiple myeloma. Dr Mohty also mentions the growing field of measurable residual disease (MRD) in myeloma, and that these fascinating topics will all be covered at this year’s COMy congress in Paris, France.
